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1.14mgr./dL. Karnofsky Scale score showed small varia-
tion: 70.3 ± 17.2 versus 72.5 ± 17.9 (n.s.). The mean score
of the PSS slightly increased after one year, indicating
improvement: 4.1 ± 1.3 versus 5.1 ± 2.1 (n.s.). The PCS
mean score of younger pts. (39.6 ± 15.0 ) was statistically
signiﬁcant worse than that of elderly (47.0 ± 8.6) at the
start (p < 0.05), but not at the end (44.4 ± 12.5) vs. (48.0
± 8.2) (n.s.). The PCS mean score of younger pts. was sta-
tistically signiﬁcant better after one year, indicating
improvement: 39.6 ± 15.0 vs. 44.4 ± 12.5 (p < 0.05). No
statistically signiﬁcant differences were found for MCS.
CONCLUSIONS: Elderly pts. showed lower loss of
HRQoL than younger pts. at start and one year later. The
HRQoL of elderly who started RRT remained stable after
one year of follow-up. The HRQoL of younger pts.
improved at one year of follow-up in physical aspects but
not in mental aspects.
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EFFECT OF ORAL LOW-DOSE HORMONAL
REPLACEMENT THERAPY (COMBINED
ESTRADIOL 1MG AND NORESTISTERONE
ACETATE 0.5MG) ON CARDIOVASCULAR RISK
IN SPANISH POSTMENOPAUSAL WOMEN
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OBJECTIVES: The aim of this study is to evaluate 
cardiovascular risk factors in a group of early post-
menopausal women and the impact of low-dose hor-
monal replacement therapy on long term cardiovascular
risk replacement therapy (LD-HRT) (combined estradiol
1mg and noretisterone acetate 0.5mg). METHODS: Epi-
demiological, observational, prospective and multicenter
study on menopausal women who initiate LD-HRT with
Activelle® (combined estradiol 1mg and noretisterone
acetate 0.5mg) for six months. Anthropometric and
demographic characteristics, dietetic and hygienic habits,
gynecologic and obstetric history were recorded at the
beginning of treatment. Blood pressure was registered and
blood lipids analysis was performed at inclusion and at
the end of study. RESULTS: A total of 728 women were
enrolled, mean age 51.6 ± 4.3 years. Smokers 18.7%
(13.5 ± 7.8cig/day. Alcohol intake was greater than 30
g/day in 14% of women. After 6 months of treatment a
signiﬁcant improvement of blood lipid levels was
achieved: cholesterol decreased from 217 ± 36.24 to 207
± 40.54mg/dl (p < 0.001) y LDL decreased from 136.4 ±
39.31 to 126.4 ± 34.14mg/dl (p < 0.05), HDL increased
from 63.4 ± 19.49 to 64.4 ± 17.55mg/dl (p < 0.001),
triglyceride level decreased from 109.4 ± 51.74 to 106 ±
42.09mg/dl. Cardiovascular Disease Risk estimated to 10
years calculated by Framingham algorithm decreased
from 6.04 ± 3.87% to 5.34 ± 3.42% (p < 0.001) Rela-
tive risk factor decreased as well (from 1.35 ± 0.85 to
1.18 ± 0.72 (p < 0.001). CONCLUSIONS: LD-HRT
(Activelle®) treatment reduces blood pressure and blood
lipids levels. This positive effect on Cardiovascular Risk
factors implies a decrease on Cardiovascular Disease Risk
estimated to 10 years.
PWH2
EFFECTIVITY AND SAFETY OF ORAL LOW-
DOSE HORMONAL REPLACEMENT THERAPY
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OBJECTIVES: The aim of this study is to evaluate effec-
tivity and safety of low-dose hormonal replacement
therapy (LD-HRT) (combined estradiol 1mg and noretis-
terone acetate 0.5mg) in a group of early postmenopausal
women. METHODS: Epidemiological, observational,
prospective and multicenter study on menopausal women
who initiate LD-HRT Activelle® (combined estradiol 
1mg and noretisterone acetate 0.5mg). Anthropometric
and demographic characteristics, dietetic and hygienic
habits, gynecologic and obstetric history of patients 
were recorded. Menopausal symptoms were measured
using kupperman index (KI) scores: hemorrhages, vertigo,
fatigue, arthralgia, headache, palpitation, and pruritus.
After 6 months of treatment, menopausal symptoms were
registered. Lineal regression model was played to quan-
tify the response to treatment. RESULTS: A total of 728
women were enrolled, mean age 51.6 ± 4.3 years. 98.8%
of women improved their symptomatology, mean
decrease of KI score was 13.46 ± 7.73 points (from 19.98
± 8.53 to 6.41 ± 5.83). In 23.9% of women KI score
decrease was a value included in the interval between 18
and 24. Fulﬁllment of treatment was observed in 82.6%
of women. Adverse events were reported in 22 patients
(3% of total). Effectivity of treatment predicting factors
resulted: greater KI score, fulﬁllment of treatment, and
initiate treatment as a result of de novo diagnose of
menopause. (R2(ad) = 65.10%). CONCLUSIONS: LD-
HRT achieves a signiﬁcant improvement on climacteric
symptomatology. Tolerability of treatment is conﬁrmed
by the high rate of fulﬁllment and the low rate of adverse
events reported.
